Ocular Therapeutix, Inc. (OCUL): Price and Financial Metrics


Ocular Therapeutix, Inc. (OCUL): $3.19

0.18 (+5.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OCUL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OCUL POWR Grades


  • Quality is the dimension where OCUL ranks best; there it ranks ahead of 75.25% of US stocks.
  • OCUL's strongest trending metric is Momentum; it's been moving down over the last 179 days.
  • OCUL ranks lowest in Growth; there it ranks in the 6th percentile.

OCUL Stock Summary

  • OCUL's price/sales ratio is 8.84; that's higher than the P/S ratio of 83.43% of US stocks.
  • Revenue growth over the past 12 months for Ocular Therapeutix Inc comes in at 150.08%, a number that bests 94.73% of the US stocks we're tracking.
  • In terms of volatility of its share price, OCUL is more volatile than 88.66% of stocks we're observing.
  • Stocks that are quantitatively similar to OCUL, based on their financial statements, market capitalization, and price volatility, are FORM, AAOI, GTHX, MRAM, and IVAC.
  • OCUL's SEC filings can be seen here. And to visit Ocular Therapeutix Inc's official web site, go to www.ocutx.com.

OCUL Valuation Summary

  • In comparison to the median Healthcare stock, OCUL's price/sales ratio is 557.89% higher, now standing at 25.
  • Over the past 86 months, OCUL's price/sales ratio has gone down 2156.5.
  • Over the past 86 months, OCUL's EV/EBIT ratio has gone up 6.

Below are key valuation metrics over time for OCUL.

Stock Date P/S P/B P/E EV/EBIT
OCUL 2021-08-31 25.0 10.1 -7.9 -7.0
OCUL 2021-08-30 25.5 10.2 -8.0 -7.1
OCUL 2021-08-27 26.1 10.5 -8.2 -7.4
OCUL 2021-08-26 25.2 10.2 -7.9 -7.1
OCUL 2021-08-25 25.0 10.1 -7.9 -7.0
OCUL 2021-08-24 24.5 9.9 -7.7 -6.8

OCUL Growth Metrics

    Its 2 year price growth rate is now at -11.29%.
  • Its 3 year net income to common stockholders growth rate is now at -47.26%.
  • Its 2 year cash and equivalents growth rate is now at -22.64%.
OCUL's revenue has moved up $41,380,000 over the prior 34 months.

The table below shows OCUL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 43.522 -65.55 -6.553
2021-09-30 38.562 -56.643 -88.315
2021-06-30 32.285 -57.319 -102.916
2021-03-31 22.136 -52.059 -131.003
2020-12-31 17.403 -53.554 -155.636
2020-09-30 12.31 -66.775 -96.041

OCUL's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OCUL has a Quality Grade of C, ranking ahead of 60.31% of graded US stocks.
  • OCUL's asset turnover comes in at 0.155 -- ranking 219th of 682 Pharmaceutical Products stocks.
  • CASI, ONVO, and DRNA are the stocks whose asset turnover ratios are most correlated with OCUL.

The table below shows OCUL's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.155 0.903 -1.479
2021-03-31 0.125 0.903 -1.953
2020-12-31 0.129 0.880 -2.245
2020-09-30 0.138 0.818 -1.315
2020-06-30 0.084 0.642 -1.377
2020-03-31 0.077 0.525 -1.196

OCUL Price Target

For more insight on analysts targets of OCUL, see our OCUL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $23.43 Average Broker Recommendation 1.43 (Moderate Buy)

OCUL Stock Price Chart Interactive Chart >

Price chart for OCUL

OCUL Price/Volume Stats

Current price $3.19 52-week high $15.32
Prev. close $3.01 52-week low $2.91
Day low $2.91 Volume 405,303
Day high $3.19 Avg. volume 636,982
50-day MA $4.10 Dividend yield N/A
200-day MA $6.76 Market Cap 244.86M

Ocular Therapeutix, Inc. (OCUL) Company Bio


Ocular Therapeutix is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. The company was founded in 2006 and is based in Bedford, Massachusetts.


OCUL Latest News Stream


Event/Time News Detail
Loading, please wait...

OCUL Latest Social Stream


Loading social stream, please wait...

View Full OCUL Social Stream

Latest OCUL News From Around the Web

Below are the latest news stories about Ocular Therapeutix Inc that investors may wish to consider to help them evaluate OCUL as an investment opportunity.

Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 23, 2022

Ocular Therapeutix To Report Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference

Business Wire | February 22, 2022

Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2021 Financial Results

BEDFORD, Mass., February 22, 2022--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report fourth quarter and year-end financial results on Monday, February 28, 2022, after the market close. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference

Yahoo | February 22, 2022

Ocular Therapeutix™ Announces Upcoming Presentation of Interim OTX-TKI Phase 1 Clinical Trial Data at Angiogenesis, Exudation, and Degeneration 2022 Meeting and OTX-TIC Phase 1 Clinical Trial at Glaucoma 360

BEDFORD, Mass., February 11, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced its intention to present data at two medical meetings. Data from the Phase 1 Australian-based clinical trial of OTX-TKI, an axitinib intravitreal implant for the treatment of patients with wet age-related macular degeneration (wet AMD) and other retinal

Yahoo | February 11, 2022

Ocular Therapeutix owner buys 50,000 shares worth ~$300K (NASDAQ:OCUL)

Ocular Therapeutix <> 10% owner, Summer Road LLC, bought 50,000 shares of the company in a price range of $5.78-6.45, worth ~$300K.This brings his total share holding to

Seeking Alpha | January 19, 2022

Read More 'OCUL' Stories Here

OCUL Price Returns

1-mo -14.48%
3-mo -42.21%
6-mo -51.22%
1-year -78.17%
3-year 28.63%
5-year -71.08%
YTD -54.23%
2021 -66.33%
2020 424.05%
2019 -0.75%
2018 -10.56%
2017 -46.83%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7826 seconds.